Abstract
Purpose
The purpose of this work was to retrospectively determine the value of intensity-modulated radiotherapy (IMRT) in patients with laryngeal and hypopharyngeal squamous cell carcinoma (LHSCC), on outcome and treatment-related toxicity compared to 3-dimensional conformal radiotherapy (3D-CRT).
Materials and methods
A total of 175 consecutive patients were treated between 2007 and 2012 at our institution with curative intent RT and were included in this study: 90 were treated with 3D-CRT and 85 with IMRT. Oncologic outcomes were estimated using Kaplan–Meier statistics; acute and late toxicities were scored according to the Common Toxicity Criteria for Adverse Events scale v 3.0.
Results
Median follow-up was 35 months (range 32–42 months; 95% confidence interval 95 %). Two-year disease-free survival did not vary, regardless of the technique used (69 % for 3D-CRT vs. 72 %; for IMRT, p = 0.16). Variables evaluated as severe late toxicities were all statistically lower with IMRT compared with 3D-CRT: xerostomia (0 vs. 12 %; p < 0.0001), dysphagia (4 vs. 26 %; p < 0.0001), and feeding-tube dependency (1 vs 13 %; p = 0.0044). The rates of overall grade ≥ 3 late toxicities for the IMRT and 3D-CRT groups were 4.1 vs. 41.4 %, respectively (p < 0.0001).
Conclusion
IMRT for laryngeal and hypopharyngeal cancer minimizes late dysphagia without jeopardizing tumor control and outcome.
Zusammenfassung
Ziel
Das Ziel dieser Studie war es, retrospektiv den Nutzen der intensitätsmodulierten Strahlentherapie (IMRT) in der Behandlung von Patienten mit Plattenepithelkarzinom von Kehlkopf und Hypopharynx (LHSCC) zu bewerten und mit dem Outcome und den Spätfolgen der 3-D-konformalen Strahlentherapie (3D-CRT) zu vergleichen.
Material und Methoden
Insgesamt wurden zwischen Januar 2007 und Dezember 2012175 LHSCC-Patienten mit einer RT behandelt und in die Studie aufgenommen: 85 Patienten wurden mit 3D-CRT und 90 Patienten mit IMRT behandelt.Das onkologische Outcome wurde mittels Kaplan-Meier-Statistik ermittelt und Akut- und Spättoxizitäten anhand der CTCAE v.3 (Common Toxicity Criteria for Adverse Events v 3.0) bewertet.
Ergebnisse
In Dreiviertel der Fälle lag eine lokal fortgeschrittene Erkrankung vor. Die durchschnittliche Nachbeobachtungszeit lag bei35 Monaten (32–42 Monate, 95%-Konfidenzintervall 95 %). Unabhängig von der angewandten RT-Technik betrug das krankheitsfreie 2-Jahres-Überleben 71 % (69 % für 3D-CRT vs. 72 % für IMRT; p = 0,16). Alle bezüglich der Spättoxizität evaluierten Parameter zeigten nach IMRT signifikant günstigere Werte als nach 3D-CRT: Xerostomie (0 vs. 12 %; p < 0,0001), Dysphagie (4 vs. 26 %; p < 0,0001) und PEG-Abhängigkeit (1 vs. 13 %; p = 0,0044). Die Langzeittoxizität (Grad ≥ 3) war nach IMRT bedeutend geringer ausgeprägt als nach 3D-CRT (4,1 vs. 41,4 %; p < 0,0001).
Schlussfolgerung
Die IMRT von LHSCC führt zu einer vergleichbaren Tumorkontrolle wie 3D-CRT und verringert die Inzidenz und den Schweregrad von Spätfolgen wie Dysphagie deutlich.
Similar content being viewed by others
References
Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26:3770–3776
Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845–852
Blanchard P, Tao Y, Veresezan O, Lusinchi A, Le Ridant AM, Janot F, Daly-Schveitzer N, Bourhis J (2012) Definitive radiotherapy for squamous cell carcinoma of the pyriform sinus. Radiother Oncol 105:232–237
Brahme A (1988) Optimization of stationary and moving beam radiation therapy techniques. Radiother Oncol 12:129–140
Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S, Murthy V, Budrukkar A, Dinshaw K, Prabhash K et al (2012) Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol 104:343–348
Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS, Lee AW (2011) Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 79:420–428
Daly ME, Le QT, Maxim PG, Loo BW, Jr, Kaplan MJ, Fischbein NJ, Pinto H, Chang DT (2010) Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 76:1339–1346
Chen AM, Farwell DG, Luu Q, Vazquez EG, Lau DH, Purdy JA (2012) Intensity-modulated radiotherapy is associated with improved global quality of life among long-term survivors of head-and-neck cancer. Int J Radiat Oncol Biol Phys 84:170–175
Butler EB, Teh BS, Grant WH, 3rd, Uhl BM, Kuppersmith RB, Chiu JK, Donovan DT, Woo SY (1999) Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 45:21–32
Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA (2003) Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 55:312–321
Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12:127–136
Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA (2009) Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 74:1–8
Toledano I, Graff P, Serre A, Boisselier P, Bensadoun RJ, Ortholan C, Pommier P, Racadot S, Calais G, Alfonsi M et al (2012) Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03. Radiother Oncol 103:57–62
Lambrecht M, Nevens D, Nuyts S (2013) Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer. Strahlenther Onkol 189:223–229
Daly ME, Le QT, Jain AK, Maxim PG, Hsu A, Loo BW, Jr, Kaplan MJ, Fischbein NJ, Colevas AD, Pinto H et al (2011) Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx. Head Neck 33:103–111
Studer G, Lutolf UM, Davis JB, Glanzmann C (2006) IMRT in hypopharyngeal tumors. Strahlenther Onkol 182:331–335
Al-Mamgani A, Mehilal R, van Rooij PH, Tans L, Sewnaik A, Levendag PC (2012) Toxicity, quality of life, and functional outcomes of 176 hypopharyngeal cancer patients treated by (chemo)radiation: the impact of treatment modality and radiation technique. Laryngoscope 122:1789–1795
Lee NY, O’Meara W, Chan K, Della-Bianca C, Mechalakos JG, Zhung J, Wolden SL, Narayana A, Kraus D, Shah JP et al (2007) Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 69:459–468
Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A (2007) Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68:1289–1298
Eisbruch A, Kim HM, Feng FY, Lyden TH, Haxer MJ, Feng M, Worden FP, Bradford CR, Prince ME, Moyer JS et al (2011) Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys 81:e93–99
Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE et al (2008) Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 72:1110–1118
Dirix P, Abbeel S, Vanstraelen B, Hermans R, Nuyts S (2009) Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 75:385–392
Mortensen HR, Jensen K, Aksglaede K, Behrens M, Grau C (2013) Late dysphagia after IMRT for head and neck cancer and correlation with dose-volume parameters. Radiother Oncol 107:288–294
Astreinidou E, Dehnad H, Terhaard CH, Raaijmakers CP (2004) Level II lymph nodes and radiation-induced xerostomia. Int J Radiat Oncol Biol Phys 58:124–131
Lee WT, Akst LM, Adelstein DJ, Saxton JP, Wood BG, Strome M, Butler RS, Esclamado RM (2006) Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation. Head Neck 28:808–812
Haderlein M, Semrau S, Ott O, Speer S, Bohr C, Fietkau R (2014) Dose-dependent deterioration of swallowing function after induction chemotherapy and definitive chemoradiotherapy for laryngopharyngeal cancer. Strahlenther Onkol 190:192–198
Levendag PC, Teguh DN, Voet P, van der Est H, Noever I, de Kruijf WJ, Kolkman-Deurloo IK, Prevost JB, Poll J, Schmitz PI et al (2007) Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 85:64–73
Jensen K (2007) Measuring side effects after radiotherapy for pharynx cancer. Acta Oncol 46:1051–1063
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Acknowledgments
The authors would like to thank Newmed publishing for English editing and Ursula Nestle for German editing.
Conflict of interest
A. Modesto, A. Laprie, L. Vieillevigne, P. Graff, J. Sarini, S. Vergez, J.-P. Delord, J.-C. Farenc, E. Vigarios, T. Filleron, and M. Rives state that there are no conflicts of interest.
All studies on humans described in the present manuscript were carried out with the approval of the responsible ethics committee and in accordance with national law and the Helsinki Declaration of 1975 (in its current, revised form). Informed consent was obtained from all patients included in studies.
Rights and permissions
About this article
Cite this article
Modesto, A., Laprie, A., Vieillevigne, L. et al. Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer. Strahlenther Onkol 191, 225–233 (2015). https://doi.org/10.1007/s00066-014-0767-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-014-0767-1
Keywords
- Squamous cell carcinoma of the head and neck
- Larynx
- Hypopharynx
- Intensity-modulated radiotherapy
- Deglutition disorders